Trial Profile
A pharmacist-led monitoring program of sunitinib in patients with metastatic renal-cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 12 Dec 2015 New trial record